BioLineRx, Hemispherian disclose promising data for glioblastoma candidate
BioLineRx (NASDAQ:BLRX) and Hemispherian AS announced encouraging preclinical data for their oncology candidate GLIX1, showcasing the experimental drug’s potential to combat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.
The Tel Aviv, Israel- and Oslo, Norway-based biopharmaceutical partners reported that orally administered GLIX1 demonstrated robust, dose-dependent anti-tumor activity across three distinct orthotopic cell-derived xenograft (CDX) models.
The studies revealed significant tumor growth inhibition and a clear survival benefit following treatment at all evaluated dose levels, with the most pronounced therapeutic effects observed at higher concentrations.
Crucially, GLIX1 achieved a profound therapeutic response in a newly completed patient-derived xenograft (PDX) model engineered to be resistant to temozolomide (TMZ)—the current standard-of-care chemotherapy for glioblastoma.
While TMZ showed no therapeutic effect on the resistant tumor tissue in subcutaneous models, GLIX1 produced a robust anti-tumor response, highlighting its ability to bypass established chemoresistance pathways.
GLIX1 operates as a first-in-class, brain-penetrating small molecule designed to activate the ten-eleven translocation methylcytosine dioxygenase 2 (TET2) pathway.
By restoring TET2 function, the therapeutic agent selectively exploits DNA repair vulnerabilities in malignant cells, overwhelming their internal replication repair capacity to trigger selective tumor cell death without damaging healthy brain tissue.
The preliminary laboratory findings provide strong mechanistic support for the companies’ ongoing Phase 1/2a first-in-human clinical trial.
The study is currently evaluating the safety, pharmacokinetics, and initial efficacy of GLIX1 in patients with recurrent and progressive glioblastoma as well as other high-grade gliomas.
The initial dose-escalation phase of the clinical trial aims to enroll up to 30 participants across leading neuro-oncology centers in the United States.
Management indicated that preliminary data from the initial phase are anticipated in the first half of 2027, which will serve as the baseline to establish optimal parameters for subsequent Phase 2a combination studies.
